Immune Response to SARS-CoV-2 Vaccines

Area of Science:

• Immunology
• Vaccinology
• Virology

Background:

• Established knowledge of SARS and MERS coronaviruses and veterinary vaccines informed rapid COVID-19 vaccine development.
• Previous coronavirus vaccine development for humans had not been achieved in under a year.

Purpose of the Study:

• To review the immune response to SARS-CoV-2 infection.
• To explain the mechanisms of action for various COVID-19 vaccine platforms.
• To summarize adjuvants used in COVID-19 vaccine formulations.

Main Methods:

• Literature review of scientific publications on COVID-19 vaccines.
• Analysis of vaccine candidate targeting strategies, primarily the SARS-CoV-2 spike protein.
• Compilation of data on different vaccine technologies and their immune responses.

Main Results:

• Multiple vaccine platforms, including mRNA, adenoviral vector, inactivated virus, and subunit vaccines, have been developed for SARS-CoV-2.
• The spike protein is a common target for most COVID-19 vaccine candidates.
• Various adjuvants are employed to enhance the immunogenicity of COVID-19 vaccines.

Conclusions:

• The rapid development of diverse COVID-19 vaccines demonstrates significant advancements in vaccinology.
• Understanding immune responses and vaccine mechanisms is crucial for combating SARS-CoV-2.
• Continued research into adjuvants may further optimize vaccine efficacy.